A Study of BL-B01D1 in Combination With Osimertinib Versus Osimertinib as First-Line Treatment in Patients With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- First Posted Date
- 2025-02-20
- Last Posted Date
- 2025-05-02
- Lead Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
- Target Recruit Count
- 696
- Registration Number
- NCT06838273
- Locations
- 🇨🇳
Shanghai East Hospital, Shanghai, Shanghai, China
A Study of BL-M07D1 Versus T-DM1 in the Adjuvant Treatment of HER2-positive Breast Cancer With Residual Invasive Cancer After Neoadjuvant Therapy
- First Posted Date
- 2025-02-17
- Last Posted Date
- 2025-06-24
- Lead Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
- Target Recruit Count
- 1450
- Registration Number
- NCT06830889
- Locations
- 🇨🇳
Jiangsu Province Hospital, Nanjing, Jiangsu, China
🇨🇳Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Chordoma
- First Posted Date
- 2025-01-22
- Last Posted Date
- 2025-05-07
- Lead Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
- Target Recruit Count
- 40
- Registration Number
- NCT06787664
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
A Study of GNC-077 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumors and Other Solid Tumors
- First Posted Date
- 2025-01-01
- Last Posted Date
- 2025-01-01
- Lead Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
- Target Recruit Count
- 20
- Registration Number
- NCT06755242
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
A Study of BL-M08D1 in Patients With Relapsed or Refractory Lymphoid Malignancies
- First Posted Date
- 2024-12-05
- Last Posted Date
- 2025-01-20
- Lead Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
- Target Recruit Count
- 22
- Registration Number
- NCT06718634
- Locations
- 🇨🇳
Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China
A Study of BL-M08D1 in Patients With Locally Advanced or Metastatic Solid Tumors
- First Posted Date
- 2024-12-05
- Last Posted Date
- 2025-03-19
- Lead Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
- Target Recruit Count
- 22
- Registration Number
- NCT06718621
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
A Study of SI-B001+SI-B003 Combined With Platinum-based Chemotherapy as First-line Treatment in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Phase 2
Recruiting
- Conditions
- Head and Neck Squamous Cell Carcinoma
- Interventions
- First Posted Date
- 2024-11-01
- Last Posted Date
- 2025-01-20
- Lead Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
- Target Recruit Count
- 60
- Registration Number
- NCT06668961
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
A Study of GNC-077 in Patients With Locally Advanced or Metastatic Non-small-cell Lung Cancer and Other Solid Tumors
- First Posted Date
- 2024-09-25
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
- Target Recruit Count
- 20
- Registration Number
- NCT06612840
- Locations
- 🇨🇳
Shanghai East Hospital, Shanghai, Shanghai, China
A Study of GNC-077 in Patients With Locally Advanced or Metastatic Breast Cancer and Other Solid Tumors
- First Posted Date
- 2024-09-24
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
- Target Recruit Count
- 20
- Registration Number
- NCT06609187
- Locations
- 🇨🇳
Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China
A Study of BL-B01D1 in Patients With Recurrent Glioblastoma
Phase 2
Recruiting
- Conditions
- Recurrent Glioblastoma
- Interventions
- Drug: BL-B01D1 for Injection
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2025-05-07
- Lead Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
- Target Recruit Count
- 20
- Registration Number
- NCT06598787
- Locations
- 🇨🇳
Beijing Tiantan Hospital, Capital Medical University, Beijing, Beijing, China